Stay updated on DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe reference to 'AstraZeneca UK Limited' has been removed, while 'AstraZeneca' remains mentioned on the page.SummaryDifference0.1%
- Check22 days agoChange DetectedThe page has been updated to reflect that the study is now active and not recruiting, with a total of 30 locations listed. Additionally, several past dates and contact information have been removed.SummaryDifference6%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.9%
- Check44 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check58 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has updated the intervention type and contact information for the Principal Investigator, while also removing the previous version details.SummaryDifference3%
Stay in the know with updates to DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.